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ABSTRACT
Background: Lung cancer seems to have different epidemiological, biomolecular 
and clinical characteristics in females than in males, with a better prognosis for women. 
The aim of the study is to determine gender differences in lung adenocarcinoma in 
terms of androgen (AR), estrogen (ER)α and progesterone (PgR) receptors expression 
and their impact on outcome.
Results: Overall survival was significantly better in ERα and in PgR positive lung 
adenocarcinoma patients (median survival 45 vs. 19 months).
Eight out of 62 patients showed positive expression of nuclear (n) AR and 18 of 
cytoplasmic (c) AR with a significantly better survival (49 vs. 19 and 45 vs. 19 months, 
respectively). There was a significant difference in survival between patients with 
vs. without c-AR expression (30 vs. 17 months). Finally, in the subgroup of women, 
median survival was greater in positive expression of c-AR than for women with 
negative c-AR (45 vs. 21 months).
Materials and Methods: We conducted an analysis on a cohort of 62 patients with 
advanced NSCLC treated at our institution. We investigated the immunohistochemical 
expression of n/c AR, ERα and PgR in 62 NSCLC and we correlated it with patients’ 
clinic-pathologic characteristics and with prognosis.
Conclusions: Our results showed that the positive expression of one hormonal 
receptor could represent a prognostic factor.
Furthermore our study suggests that AR should become object of close 
examination in a larger series of lung adenocarcinoma patients, also for selection of 
the patients with best prognosis that can perform more chemotherapy lines.
INTRODUCTION
Lung malignant neoplasms represent very common 
tumors and the leading cause of mortality for cancer 
worldwide [1].
Nowadays, epidemiological data show an exponential 
increase in its incidence and mortality in women.
Gender discrepancies in lung cancer incidence 
partially underlay documented differences in tobacco 
habit. Only in the last years smoke became also a female 
habit [2] and several studies showed females as more 
predisposed to smoke tumorigenesis than men [3, 4].
Furthermore lung cancer in women seems to 
have different characteristics than in men; presenting 
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unfavorable trend considering incidence and survival for 
females.
The distribution of histological types is significantly 
different: adenocarcinoma is the principal histotype in 
women and it is also the most frequent histologic type of 
NSCLC in non-smokers and young people [5, 6, 7, 8].
Moreover the literature data suggest that females 
present a greater outcome than men, probably for 
the influence of female hormones levels on drug 
pharmacokinetics.
Gender differences in lung disease have proposed a 
responsibility of estrogens.
One of the greatest biological differences between 
men and women, indeed, is the presence of female sex 
hormones and a growing number of studies suggest 
that estrogens and progesterons, may activate lung 
carcinogenesis.
Some studies on transgenic mice suggest that 
androgens may contribute, at least in part, to the 
development and/or progression of lung cancer, too. 
Androgens may, in fact, enhance the proliferative effect 
of estrogens [9] (Figure 1).
Nevertheless, an exhaustive analysis of all hormonal 
receptors has not been conducted, yet.
Our study wanted to establish whether the different 
hormonal patterns (estrogens, progesterons and androgens 
receptors expression) have a clinical impact on outcome in 
lung adenocarcinoma also by sex.
RESULTS
We conducted an analysis of a cohort of 62 patients 
(pts) with stage IIIb or IV NSCLC managed at the 
Department of Medical Oncology at our Institution. The 
ERα, PgR and n-AR (nuclear androgen receptors) and c-AR 
(cytoplasmic androgen receptors) expressions were evaluated. 
Patients’ clinical characteristics are summarized in Table 1.
All women (26%) included in the study were in 
postmenopausal status.
Median follow up resulted 55.38 months (range 
1.02-88.59).
Median OS (mOS) arose 19.5 months (range 0.92 
- 89 months) and median PFS reached 9 months (range 
1.02 - 68 months).
Figure 1: Different signaling pathway of androgen.
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The results of ERα, PgR and n/c-AR expression 
analysis are summarized in Tables 2–3 and Figure 2.
The subgroup of patients with n-AR positive 
expression were all men (7/7=100%), mainly smokers 
(6/7=85.7%) with stage IV at onset of disease (42.9%) and 
lung metastasis (42.9%).
The subgroup of patients with c-AR positive 
expression included mostly men (7/9=77.8%), 
smokers (7/9=77.8%), with stage IV at onset of disease 
(6/9=66.7%).
The small subgroup with positive expression of 
ER and PgR included females (2/2 =100%), with stage 
Table 1: Clinic-pathological features of 62 patients examined for hormones receptor expression
CLINIC-PATHOLOGICAL FEATURES OF 62 PATIENTS WITH NSCLC
GENDER N.
MALES 36 (58%)
FEMALES 26 (42%)
AGE
MEDIAN [RANGE] 67,5 MONTHS (34-85)
STAGE OF DISEASE AT INITIAL DIAGNOSIS
I 4 (6,4%)
IIA 4 (6,4%)
IIB 3(4,8%)
IIIA 10 (16,1%)
IIIB 6 (9,7%)
IV 35 (56,5%)
IIIB/IV 41 (66,1%)
SMOKING HABIT
YES 37 (59,7%)
NO 21 (33,9%)
UNKNOWN 4 (6,4%)
PERFORMANCE STATUS (ECOG)
0 35 (56,5%)
1 25 (40,3%)
2 2 (3,2%)
SITE OF METASTASIS
BONE 22 (35,4%)
CNS 9 (14,5%)
LYMPH-NODES 8 (12,9%)
PLEURA 14 (22,6%)
LIVER 6 (9,7%)
LUNG 22 (35,4%)
ADRENAL GLAND 2 (3,2%)
OTHER 412 (66,13,2%)
DEATH
YES 44 (71%)
NO 18 (29%)
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II lung adenocarcinoma at diagnosis (2/2=100%) and 
subsequently developing lymph-node metastasis (2/2 
=100%). These data are widely illustrated in Table 4.
OS was significantly better in ER expressed vs. 
ER negative and in PgR exhibited vs PgR negative lung 
adenocarcinoma patients (median survival=45 months 
vs. 19 months in both groups, HR=0.38 [95% confidence 
interval (CI)=0.16-0.93], p=0.03 and HR=0.42 [95% 
CI=0.15-0.92], p= 0.04, respectively).
Better progression free survival (PFS) in ER and/
or PgR positivity patients was showed, although not 
statistically significant (Figure 3).
Table 3: Positive and negative expression of hormones receptors by sex
Sex ER PgR n-AR c-AR N. (% By Sex)
Females Negative Negative Negative Negative 18 (69.3)
Females Negative Negative Negative Positive 2 (7.7)
Females Negative Positive Negative Negative 1 (3.8)
Females Positive Positive Negative Negative 3 (11.6)
Females Positive Negative Negative Negative 1 (3.8)
Females Positive Positive Positive Negative 1 (3.8)
Males Negative Negative Negative Negative 20 (55.6)
Males Negative Negative Negative Positive 7 (19.4)
Males Negative Negative Positive Negative 7 (19.4)
Males Positive Negative Negative Positive 1 (2.8)
Males Positive Positive Positive Positive 1 (2.8)
Table 2: Hormonal receptor expression analysis
Receptor expression 
analysis
(62 patient in total)
ER PgR Nuclear AR Cytoplasmic AR
+ - + - + - + -
5 (8%) 57 (92%) 4 (6%) 58 (94%) 8 (13%) 8 (13%) 18 (29%) 44 (71%)
Figure 2: Immunohistochemical staining: ER; PgR; AR. A. immunohistochemical staining for ER (clone 1D5): nuclear positivity 
(total magnification 200x) - B. immunohistochemical staining for PgR (Clone PgR636): nuclear positivity (total magnification 200x) - 
C. immunohistochemical staining for AR (Clone F39.4.1): nuclear positivity (total magnification 200x).
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n-AR expression was positive in 8 patients (12.9%, 
7 males and 1 female) and it was negative in 54 patients 
(87.1%, 29 males and 25 females).
OS was significantly better in patients with AR 
expression vs. no AR expression (median survival=49 
months in n-AR positive vs. 19 months in n-AR negative 
lung adenocarcinoma, HR=0.75 [95% CI =0.54-0.96], 
p=0.03) and also in females with AR expression vs. no AR 
expression (median survival=45 months in n-AR positive 
vs. 19 months in n-AR negative lung adenocarcinoma, 
HR=0.31 [95% CI =0.04-0.68], p=0.04).
c-AR expression was positive in 18 patients (29.0%, 
15 males and 3 females) and it was negative in 44 patients 
(71.0%, 21 males and 23 females).
Furthermore there was an important difference in 
OS between positive c-AR expression pts vs. negative 
ones (30 months vs. 17 months, HR=0.76 [95% CI =0.46-
0.95], p=0.02).
Finally, in the category of female patients, median 
survival was greater for those who showed a positive c-AR 
than for women with negative c-AR (45 months vs. 21 
months, HR=0.50 [95% CI =0.12-0.68], p=0.03).
A not-statistical significant trend in term of OS was 
observed in males according to n-AR expression (median 
survival=49 months in n-AR positive vs. 17 months in 
n-AR negative lung adenocarcinoma, p=0.49) and to c-AR 
expression (median survival=30 months in c-AR positive vs. 
16 months in c-AR negative lung adenocarcinoma, p=0.90).
Table 4: Specific characteristics of patient whit positive hormone receptors
N. Age Gender Smoke Stage Site of metastasis ER PgR n-AR c-AR
1 61 M Y IIIB Unk 0% 0% 2% 0%
2 60 M Y IV Bone 0% 0% 20% 0%
3 62 M N IIIA Lung 0% 0% 20% 0%
4 70 M Y IV Lung 0% 0% 20% 0%
5 76 M Y IIA CNS 0% 0% 20% 0%
6 78 M Y IV Lung 0% 0% 20% 0%
7 82 M Y IIIB Unk 0% 0% 30% 0%
8 68 M Y IIIA Lymph-node; pleura 0% 0% 0% 20%
9 57 M Y IV CNS; lymph-node 0% 0% 0% 40%
10 66 M N IV Bone 0% 0% 0% 40%
11 74 M Y IIB Lung; pleura 0% 0% 0% 50%
12 74 F N IV Lung; bone 0% 0% 0% 50%
13 50 M Y IV Lung; pleura 0% 0% 0% 60%
14 62 M Y IV Lung 0% 0% 0% 70%
15 71 M Y UNK Unk 0% 0% 0% 80%
16 69 F Y IV Liver 0% 0% 0% 85%
17 58 F N IV Pleura; liver; bone 0% 20% 0% 0%
18 53 F N I Unk 2% 9% 0% 0%
19 74 M Y IV CNS 3% 0% 0% 10%
20 76 F Y IIA Lymph-node 10% 8% 0% 0%
21 70 F N IIB Lung; Lymph-node, bone 15% 12% 0% 0%
22 70 M Y IIA Unk 15% 15% 12% 25%
23 62 F N IV Pleura; lung 60% 0% 0% 0%
24 68 F N IB Lung 85% 85% 50% 0%
25 61 M Y IV Lung 0% 0% 0% 0%
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DISCUSSION
The present study investigates the correlation of 
hormonal receptors expression with the clinical outcomes 
of lung adenocarcinoma patients.
In our study we showed a significant survival 
benefit in patients with positive expression of one of the 
investigated hormonal receptors (ERα, PgR or AR).
In particular, the expression of ERα, PgR or AR 
in female patients, resulted in a different prognostic 
significance according to the specific receptor.. 
Literature data on ERα, PgR and AR in NSCLC are 
rather controversial. Several studies primarily focused 
on the incidence of expression of these receptors and, 
therefore, on the importance of their role definition as 
prognostic variables, with different results. Probably 
these discrepancies are due to a lack of standardization on 
the method, on the types of antibodies used, on different 
activation of growth factors and on the interpretation of 
the same results.
Su and colleagues [10] showed a positive PgR 
expression with negative ER status in 33% of pulmonary 
neoplasms collections, with 2% of positivity for both ER 
and PgR. Conversely, Di Nunno and colleagues [11] didn’t 
discover immunohistochemical reactivity of PgR in 248 
lung cancer samples.
Ishibashi et al. demonstrated that the expression of 
PgR, detected in 106 of 228 (45%) NSCLC, is a strong 
prognostic factor. In particular PgR immunohistochemical 
positivity was significantly related to sex (p=0.0045), 
and was commonly identified in women. Furthermore 
PgR immunohistochemical reactivity was meaningfully 
recognized in adenocarcinoma (p=0.0002), appearing 
inversely related to TNM staging (p=0.0085). Finally, 
PgR expression was correlated with a significantly greater 
clinical outcome of studied population (p< 0.0001).
Our study showed ER and PgR expression in 5/62 
patients (8%) and all the three hormonal receptors positive 
in 2/62 (3%).
The role of progesterone in lung carcinogenesis is 
unclear. Estrogens and progesterons in vitro synergistically 
promote angiogenesis and increase tumor progenitor cell 
compartment as suggested by several studies.
The nuclei of tumor cells showed ERα and ERβ 
immunohistochemical positivity. In particular estrogen 
receptor α–positive pulmonary tumors percentage resulted 
38%. While, estrogen receptor β–positive lung cancer 
percentage was 34%.
Figure 3: Overall survival by hormones receptors. OS in patients stratified by: ERα, PgR, nuclear-AR and cytoplasmic-AR 
expression (0=negative, 1=positive expression).
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ERβ status showed a trend of better prognosis, not 
reaching a statistical significance (p=0.1463) [12].
A study by Yan et al. analyzed the expression 
of ERα, as performed in our research, not detecting a 
significant correlation between ERα positivity and N 
metastasis but the expression of AR could be associated 
to progression disease with involvement of N in 105 
pulmonary malignancies. The expression of estrogen 
receptors and androgen ones resulted 14% and 20%, 
respectively. Positive expression of ER wasn’t associated 
with any clinic-pathological features of studied population. 
Instead, stage III pulmonary malignancies presented 
higher rate of androgen receptor positivity than stage I. 
Furthermore, they observed a significant difference of 
androgen receptor representation between N0 and N2 
stage (p=0.0287) [13].
In our study, we showed a meaningful association of 
ERα expression with a good prognosis. Then the analysis 
of the expression of the androgens, that it has been poorly 
considered, also showed a relevant utility in understanding 
patient outcome.
Rades et al. [14] have retrospectively evaluated the 
expression of ERα, PgR and AR of the 64 patients with 
NSCLC. The results of this study showed an expression 
of ERα in 19%, of PgR in 8% and AR in 31% of cases. 
It was also found that ERα positivity is an adverse 
prognostic factor in both men and women. In particular 
supplementary subcategory evaluations showed an inverse 
relationship between ER-α positivity and locoregional 
control in females (p=0.003) and OS in males (p=0.040). 
The PgR and AR expression did not seem to have a 
prognostic role. In fact the mOS of the studied population 
was 26 months. At univariate analysis, ER-α expression 
appeared inversely related to increased OS (p=0.003) but 
was not associated with PgR (p=0.09) or AR expression 
(p=0.64).
Additionally Stabile et al. [15] analyzed the 
expression of ERα, aromatase, ERβ, EGFR and PgR in 
tumor cells and in normal cells of 183 patients suffering 
from NSCLC; ERα was significantly expressed in tumor 
cells, but has not been demonstrated a correlation with 
prognosis. ERβ, found especially and significantly in lung 
tumor tissue, was a significant predictor of worse OS. PgR 
has instead been found most frequently in normal cells 
than in tumor cells and has been identified as a positive 
prognostic factor as in our job.
Consistent with other reports, they observed that 
women had significantly better overall survival (OS) 
(p=0.014; median 4 years) and more extended time to 
progression (TTP) (p=0.009, median 3 years) compared to 
men (median OS=2 years, median TTP=1 year). ERβ was 
a significant predictor of worse OS (p=0.039; HR=1.05; 
95% CI=1.00-1.10) and EGFR approached significance 
as a predictor for worse OS (p=0.060; HR=1.29; 95% 
CI=0.99-1.68). PgR approached significance as a predictor 
for longer TTP (p=0.066; HR=0.96; 95% CI=0.91-1.00). 
ERα and aromatase as a single continuous variable showed 
no effects on survival.
PgR was also stratified with a cut-off of 7 and 
examined as total staining and by cellular compartment. 
There were no significant differences in OS, in localization 
of PgR and in sub-group analysis by sex. However, TTP 
was significantly longer in patients with high (median 
TTP=2 years) versus low (median TTP=1 year) PgR total 
scores (p=0.03).
In a retrospective study Novello et al. [16] in 130 
patients with advanced lung cancer, retrospectively 
assessed the potential correlation between sex-
linked hormone receptor expression and the clinical 
outcome of patients trated with chemotherapy. The 
immunohistochemical expression of ER-α, ER-β and 
PgR, aromatase, epidermal growth factor receptor (EGFR) 
was assessed. ER-β nuclear expression was higher than 
ER-α and PgR, whose expression was null or weak 
(mainly in women). EGFR expression was associated 
with NSCLC histology, being higher in squamous types 
and more advanced stage. In men, aromatase positive 
cases had a worse outcome (p=0.03) as well as in men 
with NSCLC and high ER-β expression. The expression 
of ERα and PgR was found extremely low and has not 
reached conclusions on the possible prognostic role and it 
is restricted to selected subgroups of patients. These data 
were confirmed in a recent meta-analysis conducted by He 
et al [17, 18, 19, 20, 21, 22].
In addition, the female lung generally presented 
increased ER-α expression than the male one, as 
mentioned by Fasco and colleagues [23].
Kawai et al. [24] examined ER expression of 132 
resected NSCLC specimens using immunohistochemical 
methods.
ER-α was found in 73% of the tissues examined and 
its expression decreased the OS (p< 0.001).
In order to explain the different expression also 
in similar studies some authors examined correlation of 
endogenous/exogenous hormones (menopausal status, 
hormones replacement therapy etc.) with characteristics 
of disease (histological grade and stage).
Pesatori et al. [25] compared women with diagnosis 
of pulmonary neoplasms with women healthy volunteers, 
collecting anamnestic data. The production of females’ 
hormones appeared protective of the carcinogenesis of 
pulmonary malignancies.
Furthermore Olivo-Marston et al. [26] showed that 
ER-α expression combined with high serum estrogen can 
predict bad life expectancy in both females and males 
(p combined < 0.001).
A limitation of our study is the limited series of 
patients and events. Nevertheless, in face of the limitations 
described, our data show as the study of androgen receptor, 
less remarkable for the neoplastic pulmonary pathology in 
literature, can become object of close examination in more 
numerous series considering the possibility to select the 
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patients with best prognosis that can benefit from more 
chemotherapy lines. Moreover, the standardization of the 
methods of ER and PgR analysis also according to the 
position of the receptors within the cell compartments 
is warranted, in order to confirm the results and to 
guide the therapeutic choice even within clinical trials 
(exogenous hormones, inhibiting hormones, combination 
of chemotherapy and hormonal therapy).
MATERIALS AND METHODS
Patients selection
This study includes consecutive patients with 
advanced NSCLC treated at the Department of Medical 
Oncology - Università Politecnica Marche, Italy.
Eligibility criteria included:
•   Age >18 years
•    Cytological/Histological evidence of lung 
adenocarcinoma
•    Eastern Cooperative Oncology Group (ECOG) 
performance status 0-2
•    Locally advanced (stage IIIB) or metastatic stage 
(stage IV)
Recorded patient characteristics and clinical 
features included: age, sex, smoking history, Eastern 
Cooperative Oncology Group (ECOG) performance 
status, menopausal status, histological type, clinical and/
or pathological stage of disease according to the TNM 
Seventh Edition (2010), mutational status of EGFR and 
k-RAS genes, data regarding all the treatments performed 
by the patients.
Response to therapy was assessed according to 
the RECIST 1.1 (Response Evaluation Criteria In Solid 
Tumors) [27] and the therapy toxicity was evaluated using 
the version 4.0 of “Common Terminology Criteria for 
Adverse Events” (CTCAE).
Pathologic analysis
The samples included transbronchial biopsies or 
pleural resection of the primary lung tumor. The estrogen, 
progesterone and androgen receptors expression was 
determined by immunohistochemistry (Figure 4A-4B-4C).
Sections of 3-5 μm thick were deparaffinized and 
the detection of antigens has occurred in automated 
manner with DAKO PT Link using ENVISION™ FLEX 
TARGET RETRIEVAL SOLUTION HIGH pH (50X) for 
Estrogen receptor (ER) and Androgen receptor (AR), and 
ENVISION™ FLEX TARGET RETRIEVAL SOLUTION 
LOW pH (50X) for Progesterone receptor (PgR) (DAKO) 
at 98°C.
After 70 minutes of treatment, sections were 
treated with 3% hydrogen peroxide and incubated at 
room temperature for 30 min with monoclonal antibodies 
against ER (Clone 1D5) (1:50, DAKO), PgR (Clone 636) 
(1:50, DAKO) and AR (Clone F39.4.1) (1:60, BioGenex). 
The staining was completed using ENVISION FLEX ™/
HRP (DAKO), as detection system; 3,3-diaminobenzidine-
hydrogen peroxide was used as chromogen.
Nuclear immunohistochemical staining was semi-
quantitatively assessed by considering the “percentage of 
positive tumor cells” (range 0-100%), independently from 
staining intensity.
Figure 4: Progression free survival by hormones receptors. PFS in patients stratified by: ERα and PgR expression (0=negative, 
1=positive expression).
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Immunostaining was assessed by two independent 
observers who were blinded to the patients’ diagnosis.
Data management and statistical analysis
Primary endpoint of this study was to evaluate the 
prognostic role of ER, PgR and AR and the correlation 
between their expression and gender, clinic-pathological 
features and clinical impact on outcome of patients with 
advanced lung adenocarcinoma.
OS was defined as the interval between the start of 
first-line treatment to death or last follow-up visit. The 
PFS was calculated from the start of treatment until the 
date of disease progression or death.
Patients who were not reported as died at the time 
of the analysis were censored at the date they were last 
known to be alive.
Survival distribution was estimated by the Kaplan-
Meier method. Significant differences in probability of 
surviving between the strata were evaluated by log-rank 
test. The association between categorical variables was 
estimated by Chi-square test.
A significant level of 0.05 was chosen to assess the 
statistical significance.
Statistical analyses were performed using MedCalc 
version 11.4.4.0 (MedCalc Software, Broekstraat 52, 9030 
Mariakerke, Belgium).
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